http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108420811-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108420811-B |
| titleOfInvention | Application of the lipid-lowering medicine in terms of hyperhomocysteinemiainjury treatment |
| abstract | The invention discloses application of the lipid-lowering medicine in terms of hyperhomocysteinemiainjury treatment.The study found that HHcy can remarkably promote the expression of bone-marrow-derived lymphocyte autophagy, thick liquid cell related gene and albumen, autophagy, thick liquid cell inhibiting factor are then lowered, and are shown that HHcy can be stimulated and are promoted bone-marrow-derived lymphocyte autophagy, thick liquid cell.Lipid-lowering medicine, which pre-processes bone-marrow-derived lymphocyte, can be reversed autophagy, thick liquid cell related gene and protein upregulation caused by HHcy and associated inhibitor downward.Research also found that HHcy can remarkably promote bone-marrow-derived lymphocyte secretion anti-β 2GPI, and lipid-lowering medicine, which pre-processes bone-marrow-derived lymphocyte, can be reversed HHcy to the facilitation of bone-marrow-derived lymphocyte secretion anti-β 2GPI.As a kind of anti-phospholipid antibody, raising will lead to anti-phospholipid antibody level in blood and increases anti-β 2GPI, has the risk for inducing antiphospholipid syndrome, can prevent the risk using lipid-lowering medicine intervention.Lipid-lowering medicine can also reduce anti-β 2GPI to the inflammatory activation of macrophage by inhibiting hyperhomocysteinemiainjury that bone-marrow-derived lymphocyte is caused to secrete anti-β 2GPI. |
| priorityDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 171.